• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国政府科技报告 >Inhaled Nitric Oxide in Preterm Infants. Evidence Report/Technology Assessment Number 195
【24h】

Inhaled Nitric Oxide in Preterm Infants. Evidence Report/Technology Assessment Number 195

机译：早产儿吸入一氧化氮。证据报告/技术评估编号195

获取原文
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Neonatal lung disease is the most common complication of preterm delivery and causes significant morbidity and mortality. Disorders of prematurity and respiratory distress are among the leading causes of infant mortality in the U.S. The use of inhaled nitric oxide (iNO) has been approved by the U.S. Food and Drug Administration for respiratory failure of the term and near-term infant and is recommended by professional societies, such as the American Academy of Pediatrics. Evidence supporting the use of iNO in term or near term infants is summarized by a Cochrane review that found that use of iNO therapy reduced the need for extracorporeal membrane oxygenation in term and near term (lesser than 34 weeks gestation) infants with respiratory failure, but did not change neurodevelopmental outcomes at two to three years of age. There is a need to consider the evidence about the use of iNO therapy in preterm infants (lesser than 34 weeks of gestation).

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号